Estrella Immunopharma, Inc. ESLAW

Full chart Compare
Set alert

Price alert · ESLAW

All alert types
0.08 USD 0.00 (+0.00%)

Nov 2, 2026, 10:56 AM EST

0.0799 Day range 0.08
0.0799 52-week range 0.08
YTD
0.00%
1 year
0.00%
Market cap
25.37M
YTD return
0.00%
1-year return
0.00%
Volume
1.28K
Open
0.11
Previous close
0.0799
Day's range
0.0799 – 0.08
52-week range
0.0799 – 0.08
Beta
-0.09

2Y 0.0000 (0.00%)

No chart data for this range yet.

Key statistics

Enterprise value
0
PEG ratio
0.00
Price / sales
0.00
Price / book
0.00
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
2.81M
Total cash
2.48M
Total debt
22.00K
Return on equity
0.00%
Short % of float
0.00%
50-day average
0.00
200-day average
0.00

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ESLAW — it syncs with the Stock Master app.

Institution ownership

ESLAW institution ownership
Holder% heldSharesValueReported
Highbridge Capital Management, LLC.20.82%416,49538.27KSep 29, 2024
Boothbay Fund Management, LLC9.49%189,89917.45KSep 29, 2024
ATW Spac Management LLC9.15%183,09916.83KSep 29, 2024
Shaw D.E. & Co., Inc.4.38%87,5008.04KSep 29, 2024
Walleye Capital LLC3.31%66,1126.08KSep 29, 2024
SkyView Investment Advisors, LLC3.13%62,5005.74KSep 29, 2024

Fund ownership

ESLAW fund ownership
Holder% heldSharesValueReported
Investment Managers Ser Tr-Robinson Opportunistic Income Fd0.59%11,8051.08KSep 29, 2024